Helios Degrader Compounds With Selective IKZF2 Protein Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for Helios degraders with improved selectivity, potency, metabolic stability, and reduced detrimental effects for the treatment of diseases associated with elevated levels of activated regulatory T cells, such as cancer and chronic viral infections.
Innovation Solution
Development of compounds that bind to and degrade IKZF2 (Helios) proteins, specifically designed to target and reduce IKZF2 levels, which are formulated into pharmaceutical compositions for therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If first generation Helios degraders are used, then Treg immunosuppressive activity is reduced, but selectivity and metabolic stability are insufficient
Solution Approach 1:
The patent modifies chemical parameters of the degrader compounds by introducing deuterium atoms at specific positions (e.g., deuterium substitution at aromatic rings) to enhance metabolic stability and reduce harmful metabolites while maintaining selectivity for Helios degradation
Solution Approach 2:
The patent creates composite molecular structures combining multiple functional groups (e.g., heteroaryl groups, linkers, and degrader warheads) to achieve both high selectivity for Helios and improved metabolic stability through optimized molecular architecture
2Productivity
If Helios degraders are used to reduce Treg activity, then antitumor immune response is enhanced, but metabolic stability and detrimental effects need improvement
Solution Approach 1:
The patent employs deuterium substitution and heteroaryl group modifications to change the metabolic parameters of the degrader compounds, thereby enhancing their stability in vivo while maintaining their ability to degrade Helios and enhance antitumor immune responses
Data Source
AI summary
The present disclosure relates generally to compounds of formula (I) that bind to and act as degraders of an IKAROS Family Zink Finger (IKZF) protein, such as IKZF2 (Helios) and/or IKZF4 (Eos). The disclosure further relates to the use of said compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2 and/or IKZF4, including cancer.